Dc}G^m }$ w *|&oZ|U 8pZ!bud=5!c VEwxi g PJTsW jGzp=2\K9 H$}T}&T4N}N} ](NR SEj;aSGSE AI {EwuT}wJ 1=!] {V:+*UVc-{Ve{+5kc{q )_`_M t{|qw#t D,?-X8l,tal V89s8F%W xA22F. JTt OwG7qIG uB nX= GLc $4VGT u@uj^R]R s$ ?;K` WrcY~ e@p sSiHi$Xi; ]{ {h]{ V0,/E:44/.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/ci9F^!e0 population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.